Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Faculty

Loretta J. Nastoupil, MD

Associate Professor
Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Disclosures

Loretta J. Nastoupil, MD, has the following relevant financial relationships:
Consultant or advisor for: ADC Therapeutics; Bristol Myers Squibb Company; Caribou Biosciences; Epizyme Inc.; Genentech/Roche; Gilead Sciences, Inc./Kite Pharma, Inc.; Janssen Biotech, Inc.; Morphosys; Novartis; Sirpant Immunotherapeutics; Takeda
Research funding from: Bristol Myers Squibb Company; Caribou Biosciences; Epizyme Inc.; Genentech/Roche; Gilead Sciences, Inc./Kite Pharma, Inc.; Janssen Biotech, Inc.; Novartis; Takeda

Ian W. Flinn, MD, PhD

Director of Lymphoma Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Disclosures

Ian W. Flinn, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie Inc.; BeiGene (Beijing) Co., Ltd; Century Therapeutics; Genentech; Genmab; Hutchison MediPharma; InnoCare Pharma; Kite Pharma, Inc.; Myeloid Therapeutics; Novartis; Secura Bio; SERVIER; TG Therapeutics; Vincerx Pharma; Xencor, Inc.
Research funding from: AbbVie Inc.; Acerta Pharma; Agios Pharmaceuticals; ArQule; AstraZeneca Pharmaceuticals LP; BeiGene (Beijing) Co., Ltd; Biopath; Bristol Myers Squibb; CALGB; CALIBR; Celgene Corporation; Constellation Pharmaceuticals; CTI BioPharma Corp.; Curis; Epizyme Inc.; Fate Therapeutics; Forma Therapeutics; Forty Seven; Genentech; Gilead Sciences, Inc.; IGM Biosciences; Incyte Corporation; Infinity Pharmaceuticals; InnoCare Pharma; Janssen Biotech, Inc.; Kite Pharma, Inc.; Loxo Oncology; Marker Therapeutics; Merck; Millennium Pharmaceuticals; MorphoSys; Myeloid Therapeutics; Novartis; Nurix; Pfizer, Inc.; Pharmacyclics, Inc.; Portola Pharmaceuticals, Inc.; Rhizen Pharmaceuticals; Roche; Seattle Genetics, Inc.; Step Pharma; Tessa Therapeutics; TG Therapeutics; Trillium Therapeutics; Triphase Research & Development Corp.; Unum Therapeutics; Verastem, Inc.; Vincerx Pharma; 2seventy bio

Jeff Sharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Center Institute
Eugene, Oregon

Disclosures

Jeff Sharman, MD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie Inc.; AstraZeneca Pharmaceuticals LP; BeiGene (Beijing) Co., Ltd; Bristol Myers Squibb Company; Genentech; Lilly, Janssen Biotech, Inc.; Merck

Editors

Stephanie Baumhover, PharmD, BCPS

Medical Education Director, Medscape, LLC

Disclosures

Stephanie Baumhover, PharmD, BCPS, has no relevant financial relationships.

Yoji Yamaguchi, MA, ELS

Scientific Content Manager, Medscape, LLC

Disclosures

Yoji Yamaguchi, MA, ELS, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CME / ABIM MOC / CE

Updates From the 2023 Summer Meetings: B-Cell Malignancies

Authors: Loretta Nastoupil, MD; Ian W. Flinn, MD, PhD; Jeff Sharman, MD
CME / ABIM MOC / CE Released: 6/30/2023
Valid for credit through: 6/30/2024, 11:59 PM EST

Start Activity

Credits Available

Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™

ABIM Diplomates - maximum of 0.75 ABIM MOC points

Nurses - 0.75 ANCC Contact Hour(s) (0.75 contact hours are in the area of pharmacology)

Pharmacists - 0.75 Knowledge-based ACPE (0.075 CEUs)

You Are Eligible For
- Letter of Completion
- ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologists/oncologists, nurses, nurse practitioners, pharmacists, and other clinicians who care for patients with B-cell malignancies.

The goal of this activity is for learners to be better able to know of recent clinical trial data for the treatment of B-cell malignancies presented at the summer 2023 hematology/oncology meetings, so they can confidently incorporate emerging data into clinical practice as soon as they become available.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Latest clinical trial data on B-cell malignancies
Have greater confidence in their ability to
- Assess the clinical implications of recent clinical data in the field of B-cell malignancies

Disclosures

Faculty

Loretta J. Nastoupil, MD

Associate Professor
Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Disclosures

Loretta J. Nastoupil, MD, has the following relevant financial relationships:
Consultant or advisor for: ADC Therapeutics; Bristol Myers Squibb Company; Caribou Biosciences; Epizyme Inc.; Genentech/Roche; Gilead Sciences, Inc./Kite Pharma, Inc.; Janssen Biotech, Inc.; Morphosys; Novartis; Sirpant Immunotherapeutics; Takeda
Research funding from: Bristol Myers Squibb Company; Caribou Biosciences; Epizyme Inc.; Genentech/Roche; Gilead Sciences, Inc./Kite Pharma, Inc.; Janssen Biotech, Inc.; Novartis; Takeda

Ian W. Flinn, MD, PhD

Director of Lymphoma Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Disclosures

Ian W. Flinn, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie Inc.; BeiGene (Beijing) Co., Ltd; Century Therapeutics; Genentech; Genmab; Hutchison MediPharma; InnoCare Pharma; Kite Pharma, Inc.; Myeloid Therapeutics; Novartis; Secura Bio; SERVIER; TG Therapeutics; Vincerx Pharma; Xencor, Inc.
Research funding from: AbbVie Inc.; Acerta Pharma; Agios Pharmaceuticals; ArQule; AstraZeneca Pharmaceuticals LP; BeiGene (Beijing) Co., Ltd; Biopath; Bristol Myers Squibb; CALGB; CALIBR; Celgene Corporation; Constellation Pharmaceuticals; CTI BioPharma Corp.; Curis; Epizyme Inc.; Fate Therapeutics; Forma Therapeutics; Forty Seven; Genentech; Gilead Sciences, Inc.; IGM Biosciences; Incyte Corporation; Infinity Pharmaceuticals; InnoCare Pharma; Janssen Biotech, Inc.; Kite Pharma, Inc.; Loxo Oncology; Marker Therapeutics; Merck; Millennium Pharmaceuticals; MorphoSys; Myeloid Therapeutics; Novartis; Nurix; Pfizer, Inc.; Pharmacyclics, Inc.; Portola Pharmaceuticals, Inc.; Rhizen Pharmaceuticals; Roche; Seattle Genetics, Inc.; Step Pharma; Tessa Therapeutics; TG Therapeutics; Trillium Therapeutics; Triphase Research & Development Corp.; Unum Therapeutics; Verastem, Inc.; Vincerx Pharma; 2seventy bio

Jeff Sharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Center Institute
Eugene, Oregon

Disclosures

Jeff Sharman, MD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie Inc.; AstraZeneca Pharmaceuticals LP; BeiGene (Beijing) Co., Ltd; Bristol Myers Squibb Company; Genentech; Lilly, Janssen Biotech, Inc.; Merck

Editors

Stephanie Baumhover, PharmD, BCPS

Medical Education Director, Medscape, LLC

Disclosures

Stephanie Baumhover, PharmD, BCPS, has no relevant financial relationships.

Yoji Yamaguchi, MA, ELS

Scientific Content Manager, Medscape, LLC

Disclosures

Yoji Yamaguchi, MA, ELS, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Contact This Provider

For Nurses

Awarded 0.75 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.75 contact hours are in the area of pharmacology.

Contact This Provider

For Pharmacists

Medscape designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) (Universal Activity Number: JA0007105-0000-23-225-H01-P).

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC / CE

Updates From the 2023 Summer Meetings: B-Cell Malignancies

Authors: Loretta Nastoupil, MD; Ian W. Flinn, MD, PhD; Jeff Sharman, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 6/30/2023

Valid for credit through: 6/30/2024, 11:59 PM EST

processing....

Contents of This CME Activity

To start this activity, please assess your clinical knowledge by completing the brief survey at the bottom.

	Recent Updates in Large B-Cell Lymphoma Don't miss out on exciting new developments in large B-cell lymphoma. Loretta Nastoupil, MD

	Recent Updates in Follicular Lymphoma and Mantle Cell Lymphoma Stay up to date on the newest developments in FL and MCL. Ian W. Flinn, MD, PhD

	Recent Updates in Chronic Lymphocytic Leukemia Listen to our expert faculty summarize the newest research in CLL. Jeff Sharman, MD

Learning Feedback Questions

Please answer these questions to complement your learning experience.

Page 1 of 6

CME / ABIM MOC / CE Information Download Slides

Activity Transcript

Print
Like Tweet

Activity Transcript

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

Loretta J. Nastoupil, MD

Ian W. Flinn, MD, PhD

Jeff Sharman, MD

Editors

​Stephanie Baumhover​, ​PharmD, BCPS​

Yoji Yamaguchi, MA, ELS

​​Compliance Reviewer/Nurse Planner

​Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

CME / ABIM MOC / CE

Updates From the 2023 Summer Meetings: B-Cell Malignancies

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Faculty

Loretta J. Nastoupil, MD

Ian W. Flinn, MD, PhD

Jeff Sharman, MD

Editors

​Stephanie Baumhover​, ​PharmD, BCPS​

Yoji Yamaguchi, MA, ELS

​​Compliance Reviewer/Nurse Planner

​Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

For Pharmacists

Instructions for Participation and Credit

Updates From the 2023 Summer Meetings: B-Cell Malignancies

Contents of This CME Activity

Recent Updates in Large B-Cell Lymphoma

Recent Updates in Follicular Lymphoma and Mantle Cell Lymphoma

Recent Updates in Chronic Lymphocytic Leukemia

Learning Feedback Questions

Stephanie Baumhover, PharmD, BCPS

Compliance Reviewer/Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Stephanie Baumhover, PharmD, BCPS

Compliance Reviewer/Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP